Biocon, Clinigene and Scirex in pact

Biocon Ltd has announced that Clinigene International, a wholly owned subsidiary of the Company and SCIREX Corporation, a wholly owned subsidiary of the Omnicom Group have signed a letter of intent (LOI) to collaborate on global clinical trials.

The LOI was signed at SCIREX's Headquarters in Pennsylvania, USA, during a recent visit by Dr Kiran Mazumdar-Shaw, chairman and managing director of the company and Dr Arvind Atignal, chief operating officer, Clinigene.

With India rapidly emerging as a key locale for clinical research, the new relationship provides SCIREX clients immediate access to well developed expertise in clinical investigation in India and provides Clinigene the opportunity to expand its markets and participate in global clinical trial programs.

Mazumdar-Shaw said that she saw the partnership as a natural evolution for Clinigene and the company given the "significant investment made over the past decade in systems, processes, and people. We are proud of the leading role we have taken in India and look forward to enabling SCIREX's clients to benefit from the quality and speed of clinical development in India."